These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 25344984)

  • 21. Prostate-specific antigen testing and prostate cancer screening.
    Djavan B; Eckersberger E; Finkelstein J; Sadri H; Taneja SS; Lepor H
    Prim Care; 2010 Sep; 37(3):441-59, vii. PubMed ID: 20705192
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Use of low free to total PSA ratio in prostate cancer screening: detection rates, clinical and pathological findings in Brazilian men with serum PSA levels <4.0 ng/mL.
    Faria EF; Carvalhal GF; dos Reis RB; Tobias-Machado M; Vieira RA; Reis LO; Nogueira L; Machado RD; Freitas CH; Magnabosco WJ; Mauad EC; Carvalho AL
    BJU Int; 2012 Dec; 110(11 Pt B):E653-7. PubMed ID: 22892057
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Unravelling the prostate-specific antigen controversy: a West of Scotland perspective.
    Zafar N; Miller S; Leburn V; Qureshi KN; Rajan P
    Scott Med J; 2014 May; 59(2):126-9. PubMed ID: 24682103
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The influence of physician recommendation on prostate-specific antigen screening.
    Pucheril D; Dalela D; Sammon J; Sood A; Sun M; Trinh QD; Menon M; Abdollah F
    Urol Oncol; 2015 Oct; 33(10):424.e1-7. PubMed ID: 26206103
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Screening for prostate cancer: present status and future perspectives].
    Ito K
    Nihon Rinsho; 2014 Dec; 72(12):2198-203. PubMed ID: 25518358
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Evaluation of (-2)proPSA in combination with total PSA and free PSA for the early detection of prostate cancer].
    Lamy PJ; Montels F; Tosi D; Leizour B; Bascoul-Mollevi C; Castan F; Roques S; Nielloud F; Rebillard X
    Ann Biol Clin (Paris); 2013; 71(5):537-44. PubMed ID: 24113439
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Advances in the application of prostate-specific antigen in the detection of early-stage prostate cancer.
    Kamoi K; Babaian RJ
    Semin Oncol; 1999 Apr; 26(2):140-9. PubMed ID: 10597725
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prostate cancer screening.
    Ragsdale JW; Halstater B; Martinez-Bianchi V
    Prim Care; 2014 Jun; 41(2):355-70. PubMed ID: 24830612
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Men's preferences and trade-offs for prostate cancer screening: a discrete choice experiment.
    Howard K; Salkeld GP; Patel MI; Mann GJ; Pignone MP
    Health Expect; 2015 Dec; 18(6):3123-35. PubMed ID: 25382490
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [[-2] proPSA: A Novel Marker of Prostate Cancer].
    Ishikura K
    Rinsho Byori; 2015 Jan; 63(1):84-93. PubMed ID: 26524883
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PCA3: from basic molecular science to the clinical lab.
    Day JR; Jost M; Reynolds MA; Groskopf J; Rittenhouse H
    Cancer Lett; 2011 Feb; 301(1):1-6. PubMed ID: 21093148
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PSA and the family physician.
    Barkin J
    Can J Urol; 2011 Apr; 18 Suppl():20-3. PubMed ID: 21501547
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Early management of prostate cancer: how to respond to an elevated PSA?
    Canto EI; Slawin KM
    Annu Rev Med; 2002; 53():355-68. PubMed ID: 11818479
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Screening for prostate cancer: the current evidence and guidelines controversy.
    Gomella LG; Liu XS; Trabulsi EJ; Kelly WK; Myers R; Showalter T; Dicker A; Wender R
    Can J Urol; 2011 Oct; 18(5):5875-83. PubMed ID: 22018148
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A comparative performance analysis of total prostate-specific antigen, percentage free prostate-specific antigen, prostate-specific antigen velocity and urinary prostate cancer gene 3 in the first, second and third repeat prostate biopsy.
    Auprich M; Augustin H; Budäus L; Kluth L; Mannweiler S; Shariat SF; Fisch M; Graefen M; Pummer K; Chun FK
    BJU Int; 2012 Jun; 109(11):1627-35. PubMed ID: 21939492
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pathology consultation on prostate-specific antigen testing.
    Noguez JH; Fantz CR
    Am J Clin Pathol; 2014 Jul; 142(1):7-15. PubMed ID: 24926079
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Screening for prostate cancer.
    Cher ML; Carroll PR
    West J Med; 1995 Mar; 162(3):235-42. PubMed ID: 7536993
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Should prostate-specific antigen screening be offered to asymptomatic men?
    van Vugt HA; Bangma CH; Roobol MJ
    Expert Rev Anticancer Ther; 2010 Jul; 10(7):1043-53. PubMed ID: 20645694
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prostate-specific antigen kinetics in localized and advanced prostate cancer.
    Fitzpatrick JM; Banu E; Oudard S
    BJU Int; 2009 Mar; 103(5):578-87. PubMed ID: 19210674
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-effectiveness of Prostate Health Index for prostate cancer detection.
    Nichol MB; Wu J; Huang J; Denham D; Frencher SK; Jacobsen SJ
    BJU Int; 2012 Aug; 110(3):353-62. PubMed ID: 22077934
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.